GeneDx Holdings/$WGS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GeneDx Holdings
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Ticker
$WGS
Sector
Primary listing
Employees
1,300
Headquarters
Website
GeneDx Holdings Metrics
BasicAdvanced
$2.1B
-
-$0.73
2.02
-
Price and volume
Market cap
$2.1B
Beta
2.02
52-week high
$170.87
52-week low
$55.17
Average daily volume
771K
Financial strength
Current ratio
2.463
Quick ratio
2.256
Long term debt to equity
33.818
Total debt to equity
36.721
Interest coverage (TTM)
-4.65%
Profitability
EBITDA (TTM)
13.422
Gross margin (TTM)
69.74%
Net profit margin (TTM)
-4.92%
Operating margin (TTM)
-2.76%
Effective tax rate (TTM)
0.55%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-1.56%
Return on equity (TTM)
-7.60%
Valuation
Price to revenue (TTM)
4.833
Price to book
6.85
Price to tangible book (TTM)
16.72
Price to free cash flow (TTM)
144.876
Free cash flow yield (TTM)
0.69%
Free cash flow per share (TTM)
0.498
Growth
Revenue change (TTM)
39.97%
Earnings per share change (TTM)
-62.25%
3-year revenue growth (CAGR)
22.13%
3-year earnings per share growth (CAGR)
-76.08%
GeneDx Holdings News
AllArticlesVideos
Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing
Business Wire·2 weeks ago
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C
Business Wire·2 weeks ago
These Analysts Slash Their Forecasts On GeneDx After Q4 Results
Benzinga·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GeneDx Holdings stock?
GeneDx Holdings (WGS) has a market cap of $2.1B as of March 24, 2026.
What is the P/E ratio for GeneDx Holdings stock?
The price to earnings (P/E) ratio for GeneDx Holdings (WGS) stock is 0 as of March 24, 2026.
Does GeneDx Holdings stock pay dividends?
No, GeneDx Holdings (WGS) stock does not pay dividends to its shareholders as of March 24, 2026.
When is the next GeneDx Holdings dividend payment date?
GeneDx Holdings (WGS) stock does not pay dividends to its shareholders.
What is the beta indicator for GeneDx Holdings?
GeneDx Holdings (WGS) has a beta rating of 2.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.